DOCSLIB.ORG

REGULATION of ADRENOCORTICOTROPHIN and ITS PRECURSORS in SMALL CELL LUNG CANCER Mary Felicity Stewart, Bsc, MB BS a Thesis Submi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
REGULATION of ADRENOCORTICOTROPHIN and ITS PRECURSORS in SMALL CELL LUNG CANCER Mary Felicity Stewart, Bsc, MB BS a Thesis Submi REGULATION OF ADRENOCORTICOTROPHIN AND ITS PRECURSORS IN SMALL CELL LUNG CANCER Mary Felicity Stewart, BSc, MB BS A Thesis submitted to the University of London for the degree of DOCTOR OF MEDICINE ProQuest Number: U553788 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest U553788 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ABSTRACT The ACTH precursor gene, pro-opiomelanocortin (POMC) is expressed in many non-pituitary tumours. In this thesis, small cell lung cancer (SCLC) cell lines have been studied as an in vitro model of the regulation of human, non-pituitary POMC. In contrast to the aggressive growth of this tumour in patients, SCLC cell lines are slow growing and difficult to establish and maintain in culture. ACTH and its precursors were quantitated by two- site immunoradiometric assays based on monoclonal antibodies. Ten cell lines (56%) secreted predominantly ACTH precursors (POMC and pro-ACTH) in the range 37-1405 pmol/1, with very little, if any, processing to ACTH. POMC RNA was demonstrated in 5 cell lines and a major transcript of approximately approximately 1350 bases was identified by Northern blot analysis in the cell line, COR L103, slightly larger than normal human pituitary (approximately 1100 bases). Incubation of SCLC cells for 10 days with hydrocortisone (500 and 1000 nM) did not inhibit intracellular POMC mRNA or ACTH precursor secretion, while this protocol produced significant inhibition in pituitary adenoma cells (AtT20). However, the dopamine agonist, bromocriptine (lOpg/ml) markedly suppressed ACTH precursor secretion following 24h and 7 days incubation. Corticotrophin releasing factor (CRF, 1000 ng/ml) had little effect on SCLC cells but significantly stimulated AtT20 and primary cultures of human pituitary cells. ACTH precursor secretion by SCLC cells was increased by dibutyryl cyclic AMP indicating that this intracellular signalling pathway is functional. These results are consistent with the clinical features of the ectopic ACTH syndrome, where ACTH circulates in precursor forms and is relatively resistant to glucocorticoid inhibition or stimulation with CRF. Thus the POMC gene is regulated in SCLC but it appears that the mechanisms differ from those operating in the anterior pituitary. 2 To: Stephen, Eleanor and Peter 3 The results presented in this thesis have not been submitted by the author for any other degree and to the best of her knowledge are her own work, except where due acknowledgement is made. 4 i ACKNOWLEDGEMENTS I am indebted to Dr. Anne White for her careful supervision and direction during the preparation of this Thesis. I wish to acknowledge the generous donations of small cell lung cancer cell lines by the following: Dr. Peter Twentyman (MRC Clinical Oncology and Radiotherapeutics Unit, Cambridge, UK). Dr. Frank Cuttitta (National Cancer Institute, Bethesda, Maryland, USA). Dr. M. Brouwer (Netherlands Cancer Institute, Amsterdam, The Netherlands). Dr. Lou de Leij (University of Groningen, The Netherlands) Dr. Gill Duchesne (Ludwig Institute for Cancer Research, Sutton, UK). I am grateful to the many clinicians at Hope Hospital, Salford and Wythenshawe Hospital, Manchester, for providing tumour samples from their patients. During the course of this project a number of collaborative studies were carried out and the contribution of others to the work described in this Thesis is detailed below. 1. The immunoradiometric assay for ACTH precursors was developed by Dr. Steven Crosby. My own contribution was to culture the pituitary and small cell lung cancer cells from which we were able to purify a POMC standard for the assay. 2. The chromatography of ACTH-related peptides was carried out jointly by Dr. Steven Crosby and me. 3. Studies of the molecular biology of POMC in small cell lung cancer cell lines were undertaken with Dr. Adrian Clark and Professor L.H. Rees (Department of Chemical Endocrinology, St. Bartholomew’s Hospital, London). 5 !f Northern and slot blot analysis of POMC, glucocorticoid receptor and ii, tyrosine amino transferase RNA were carried out by Dr. Adrian Clark and Dr. Paul Lavender (St. Bartholomew’s Hospital) and Dr. Bill Farrell (Hope Hospital). I thank Dr. Adrian Clark and Paul Lavender for carrying out one set of cell culture experiments on AtT20 cells. These experiments are identified in the text. 4. The dexamethasone binding assay was carried out by Dr. Bill Farrell and Dr. Adrian Clark with help and advice from Professor Gavin Vinson (St. Bartholomew’s Hospital). 5. Immunoradiometric assays for ACTH precursors and ACTH and cortisol radioimmunoassays were performed by Mrs Sarah Gibson, Ms Naomi Simpson and Ms Eileen Glover for which I am very grateful. 6. I carried out statistical analysis using the ’Minitab’ package with helpful advice from Sally Hollis (University of Manchester, Department of Statistical and Computational Studies). I thank Peter Crowe and Robert Weinkove for teaching me to use computer graphics. I particularly wish to thank Sarah Gibson, Steven Crosby and Bill Farrell for many useful discussions, and other staff in the Department of Medicine (Clinical Biochemistry) at Hope Hospital. Mrs. Christine Atkinson’s expert secretarial skill was invaluable in producing this manuscript and I also thank the Department of Medical Illustration for their help with photographs and figures. Finally, I wish to acknowledge Professor John G. Ratcliffe for supporting me at the outset of my project and Professor Pankaj Vadgama for continuing that support. 6 CONTENTS INTRODUCTION PAGE NOS I. ACTH IN NORMAL TISSUES 18 1. THE POMC GENE 18 2. BIOSYNTHESIS AND RELEASE OF ACTH AND RELATED PEPTIDES 20 i) Structure of the ACTH precursor, Pro-opiomelanocortin 20 (POMC) ii) Processing of POMC in the Anterior Pituitary 23 iii) The Neurointermediate Lobe 27 iv) POMC peptides in non-pituitary tissues 28 3. BIOLOGICAL ACTIONS OF POMC DERIVED PEPTIDES 29 i) ACTH 29 ii) N-POC 31 iii) The Lipotrophins and Beta-endorphin 32 4. REGULATION OF POMC EXPRESSION IN THE PITUITARY 32 i) Glucocorticoids 34 ii) Corticotrophin Releasing Factor 36 iii) Other Regulators of POMC expression 38 iv) Regulation of POMC in the Neurointermediate Lobe 40 II. MEASUREMENT OF POMC PEPTIDES 42 1. ACTH 42 2. Precursors of ACTH: POMC and Pro-ACTH 45 3. Other POMC derived peptides 46 III. HORMONES IN TUMOURS 47 1. Origin of Hormones in Lung Cancer 47 2. Nature of Hormones in Lung Cancer 50 3. Tumorigenesis: Links between Oncogenes, Autocrine 52 Growth Factors and Tumour Hormones 7 PAGE NOS IV. ACTH IN SMALL CELL LUNG CANCER (SCLC) 55 1. Clinical Aspects 55 2. Nature of ACTH related peptides produced by SCLC 56 3. The POMC gene in SCLC 58 4. Regulation of ACTH in SCLC 59 V. SCLC CELL LINES 61 1. Establishment and Characterisation of SCLC Cell Lines 61 2. Cytogenetic abnormalities and oncogene expression 65 3. Hormone Production 66 4. Autocrine growth factors 68 5. Advantages and limitations 69 VI. SUMMARY AND AIMS OF THIS THESIS 71 MATERIALS AND METHODS I Primary culture of human lung tumour cells 73 II Culture of established SCLC cell lines 77 III Culture of pituitary cells 80 IV Freezing down and retrieving cells from liquid nitrogen 82 V Methods for quantitation of tumour cells 83 VI Extraction of cell pellets for ACTH and precursors 85 VII Immunoradiometric assays for ACTH and ACTH precursor 86 peptides VIII Cortisol radioimmunoassay 91 IX Analysis of RNA 92 X Glucocorticoid binding assay 94 XI Statistical analysis 95 8 RESULTS Primary culture of lung and pituitary tumours 99 Secretion of ACTH and its precursors by SCLC cell lines 109 POMC gene expression in SCLC cell lines 121 Regulation of POMC gene expression and peptide secretion 127 in SCLC cell lines Glucocorticoids 127 Bromocriptine 167 Corticotrophin releasing factor (CRF) 177 Effect of glucocorticoid and CRF on human corticotroph 184 cells Second messenger mechanisms in SCLC cells 188 DISCUSSION Primary culture of human lung and pituitary tumours 204 ACTH precursors in SCLC cell lines 205 ACTH and ACTH precursor secretion by pituitary cells 206 Expression of POMC RNA in SCLC cells 208 Regulation of POMC gene expression and peptide secretion 209 in SCLC cells Summary and conclusions 218 9 PAGE NOS REFERENCES 220 APPENDIX I Materials 257 APPENDIX II Tables of data 272 Section 1. Peptides 273 Section 2. RNA 292 APPENDIX III Normal Probability Plots 295 APPENDIX IV Summary of results of statistical 317 analysis APPENDIX V Publications arising from this Thesis 325 10 LIST OF TABLES Page Table 1 Regulators of POMC in the anterior pituitary. 33 Table 2 Peptide hormones associated with SCLC. 51 Table 3 Composition of HITES medium for SCLC. 62 Table 4 Classification of SCLC cell lines based on 64 in vitro biological properties. Table 5 Hormone secretion by SCLC cell lines. 67 Table 6 SCLC cell lines. 78 Table 7 Primary culture of lung tumour samples. 100 Table 8 Levels of ACTH precursors and ACTH secreted 107 by human pituitary cells. Table 9 Levels of ACTH and precursor peptides in 112 supernatant medium from SCLC cell lines. Table 10 Levels of ACTH and precursor peptides in cell 113 pellet extracts from SCLC cell lines. Table 11 Levels of precursors in medium following 24h 117 incubation of SCLC cells. Table 12 ACTH precursors secreted by SCLC cells at different 119 stages of growth.
Load more

Recommended publications
  • Amylase Release from Rat Parotid Gland Slices C.L
    Br. J. P!harmnic. (1981) 73, 517-523 THE EFFECTS OF SUBSTANCE P AND RELATED PEPTIDES ON a- AMYLASE RELEASE FROM RAT PAROTID GLAND SLICES C.L. BROWN & M.R. HANLEY MRC Neurochemical Pharmacology Unit, Medical Research Council Centre, Medical School, Hills Road, Cambridge CB2 2QH 1 The effects of substance P and related peptides on amylase release from rat parotid gland slices have been investigated. 2 Supramaximal concentrations (1 F.M) of substance P caused enhancement of amylase release over the basal level within 1 min; this lasted for at least 40 min at 30°C. 3 Substance P-stimulated amylase release was partially dependent on extracellular calcium and could be inhibited by 50% upon removal of extracellular calcium. 4 Substance P stimulated amylase release in a dose-dependent manner with an ED50 of 18 nm. 5 All C-terminal fragments of substance P were less potent than substance P in stimulating amylase release. The C-terminal hexapeptide of substance P was the minimum structure for potent activity in this system, having 1/3 to 1/8 the potency of substance P. There was a dramatic drop in potency for the C-terminal pentapeptide of substance P or substance P free acid. Physalaemin was more potent than substance P (ED50 = 7 nM), eledoisin was about equipotent with substance P (ED5o = 17 nM), and kassinin less potent than substance P (ED50 = 150 nM). 6 The structure-activity profile observed is very similar to that for stimulation of salivation in vivo, indicating that the same receptors are involved in mediating these responses.
    [Show full text]
  • V·M·I University Microfilms International a Bell & Howell Information Company 300 North Zeeb Road, Ann Arbor
    Characterization of the cloned neurokinin A receptor transfected in murine fibroblasts Item Type text; Dissertation-Reproduction (electronic) Authors Henderson, Alden Keith. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 27/09/2021 18:29:56 Link to Item http://hdl.handle.net/10150/185828 1/. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed through, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note. will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Fast Cancer Uptake of 99Mtc-Labelled Bombesin (99Mtc BN1)
    in vivo 19: 1071-1076 (2005) Fast Cancer Uptake of 99mTc-labelled Bombesin (99mTc BN1) F. SCOPINARO1, G. P. DI SANTO1, A. TOFANI1, R. MASSARI2, C. TROTTA2, M. RAGONE3, S. ARCHIMANDRITIS4 and A.D. VARVARIGOU5 1Department of Scienze Radiologiche and 4Faculty of Engineering, University “La Sapienza”, Rome; 2University Hospital “San Andrea”, Rome; 3Li-Tech and ISIB-CNR, Udine and Rome, Italy; 5National Research Center,"Demokritos", Athens, Greece Abstract. In human blood, breakdown of gastrin-releasing show istant action because BN receptors (BNRs) and BNR peptide and other bombesin-related peptides occurs in less than subtypes (BNS) are the same in different tissues; however, 15 min. This quick enzymatic cleavage might impair the the action of the above peptides is prevented by their rapid diagnostic use of labelled bombesin (BN). 99mTc-labelled breakdown in the serum. bombesin (99mTc BN1) was injected intravenously and BN and BN-related peptides are neuro-hormones and dynamic uptake data were acquired for diagnosing 26 cancers neurotransmitters; the three well known human BNS show a of different origin: 15 breast, 3 prostate, 5 colo-rectal, 1 number of functions in the central nervous system (4, 5). pancreas, 2 small cell lung cancers and 1 gastrinoma. BNS is also expressed in several foetal and adult tissues, Background subtracted tumour uptake data were plotted where BN-related peptides act as releasing factors, against time and fitted with known mathematical functions. morphogens and growth factors (6-8). Finally, BN-related Twenty-three out of 26 cancers showed rapid increase of peptides, whose paracrine and autocrine production has radioactivity followed by a radioactivity plateau, with some already been mentioned, act as mitogens, growth and anti- oscillations around the average plateau value.
    [Show full text]
  • Vasoactive Intestinal Peptide Inhibits Human Small-Cell Lung Cancer Proliferation in Vitro and in Vivo (Neuropeptides͞camp͞cell Culture͞athymic Nude Mice)
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 14373–14378, November 1998 Medical Sciences Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo (neuropeptidesycAMPycell cultureyathymic nude mice) KANAME MARUNO*, AFAF ABSOOD†, AND SAMI I. SAID‡ Department of Medicine, Northport Veterans Affairs Medical Center Stony Brook, NY 11768-2290, and State University of New York, Health Sciences Center 17-040, Stony Brook, NY 11794-8172 Communicated by Susan E. Leeman, Boston University School of Medicine, Boston, MA, September 23, 1998 (received for review March 15, 1998) ABSTRACT Small-cell lung carcinoma (SCLC) is an ag- cell lines (7, 8). The cells were maintained in RPMI medium gressive, rapidly growing and metastasizing, and highly fatal 1640 containing 10 nM hydrocortisone, 5.0 mgyml insulin, 10 neoplasm. We report that vasoactive intestinal peptide inhib- mgyml transferrin, 10 nM 17b-estradiol, 30 nM sodium selen- its the proliferation of SCLC cells in culture and dramatically ite, 100 unitsyml penicillin, and 100 mgyml streptomycin suppresses the growth of SCLC tumor-cell implants in athy- (HITES medium; ref. 9). As a control, the SCLC cell line mic nude mice. In both cases, the inhibition was mediated NCI-H128 (American Type Culture Collection), which lacks apparently by a cAMP-dependent mechanism, because the VIP receptors (10), was also tested. The cells were incubated inhibition was enhanced by the adenylate cyclase activator in tissue-culture flasks in a humidified atmosphere of 5% CO2 forskolin and the phosphodiesterase inhibitor 3-isobutyl-1- in air at 37°C and grown as floating cell aggregates.
    [Show full text]
  • Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases Achim Fleischmann, Ursula Läderach, Helmut Friess, Markus W
    0023-6837/00/8012-1807$03.00/0 LABORATORY INVESTIGATION Vol. 80, No. 12, p. 1807, 2000 Copyright © 2000 by The United States and Canadian Academy of Pathology, Inc. Printed in U.S.A. Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases Achim Fleischmann, Ursula Läderach, Helmut Friess, Markus W. Buechler, and Jean Claude Reubi Division of Cell Biology and Experimental Cancer Research (AF, UL, JCR), Institute of Pathology, University of Berne, and Department of Visceral and Transplantation Surgery (HF, MWB), Inselspital, University of Berne, Berne, Switzerland SUMMARY: Overexpression of receptors for regulatory peptides in various human diseases is reportedly of clinical interest. Among these peptides, bombesin and gastrin-releasing peptide (GRP) have been shown to play a physiological and pathophysiological role in pancreatic tissues. Our aim has been to localize bombesin receptors in the human diseased pancreas to identify potential clinical applications of bombesin analogs in this tissue. The presence of bombesin receptor subtypes has been evaluated in specimens of human pancreatic tissues with chronic pancreatitis (n ϭ 23) and ductal pancreatic carcinoma (n ϭ 29) with in vitro receptor autoradiography on tissue sections incubated with 125I-[Tyr4]-bombesin or the universal ligand 125I-[D-Tyr6, ␤-Ala11, Phe13, Nle14]-bombesin(6–14) as radioligands and displaced by subtype-selective bombesin receptor agonists and antagonists. GRP receptors were identified in the pancreatic exocrine parenchyma in 17 of 20 cases with chronic pancreatitis. No measurable bombesin receptors were found in the tumor tissue of ductal pancreatic carcinomas, however, GRP receptors were detected in a subset of peritumoral small veins in 19 of 29 samples.
    [Show full text]
  • A 0.70% E 0.80% Is 0.90%
    US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.
    [Show full text]
  • 251-Bolton-Hunter- Labeled Substance P Binding Sites in Rat Spinal Cord’
    0270.6474/65/0505-1293$02.00/O The Journal of Neuroscience Copyright 0 Society for Neuroscience Vol. 5, No. 5, pp. 1293-1299 Printed in U.S.A. May 1985 Characterization and Segmental Distribution of ‘251-Bolton-Hunter- labeled Substance P Binding Sites in Rat Spinal Cord’ CLIVEL G. CHARLTON’ AND CINDA J. HELKE Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 Abstract al., 1982) are two sources for SP in the ventral horn. The nucleus interfascicularis hypoglossi also supplies SP-containing nerve termi- Substance P (SP) is widely distributed in the spinal cord nals to the IML cells of origin for autonomic preganglion fibers (Helke and has been implicated as a neurotransmitter in several et al., 1982). spinal cord neuronal systems. To investigate SP receptors in Functional studies support the concept of a neurotransmOitter role the spinal cord, 1251-Bolton-Hunter-SP (‘*‘I-BH-SP) was used for SP in the spinal cord. Nociception (Piercey et al., 1981; Akerman to identify and characterize spinal cord binding sites for the et al., 1982; Fasmer and Post, 1983) motor control (Otsuka and peptide. The binding of ‘*%BH-SP had the following charac- Konishi, 1977; Yanagisawa et al., 1982) and certain autonomic teristics: high affinity; time, temperature, and membrane con- functions (Loewy and Sawyer, 1982; Keeler and Helke, 1984) are centration dependent; reversible; and saturable. The KS0 of modulated by spinal cord SP. In addition, SP receptors in the spinal SP in whole spinal cord was 0.46 nM as compared with 0.95, cord have been demonstrated by iontophoretic studies in which SP 60, and 150 nM for physalaemin, eledoisin, and kassinin.
    [Show full text]
  • Potential for Gut Peptide-Based Therapy in Postprandial Hypotension
    nutrients Review Potential for Gut Peptide-Based Therapy in Postprandial Hypotension Malcolm J. Borg 1, Cong Xie 1 , Christopher K. Rayner 1, Michael Horowitz 1,2, Karen L. Jones 1,2 and Tongzhi Wu 1,2,* 1 Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide 5000, Australia; [email protected] (M.J.B.); [email protected] (C.X.); [email protected] (C.K.R.); [email protected] (M.H.); [email protected] (K.L.J.) 2 Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide 5000, Australia * Correspondence: [email protected]; Tel.: +61-8-8313-6535 Abstract: Postprandial hypotension (PPH) is an important and under-recognised disorder resulting from inadequate compensatory cardiovascular responses to meal-induced splanchnic blood pool- ing. Current approaches to management are suboptimal. Recent studies have established that the cardiovascular response to a meal is modulated profoundly by gastrointestinal factors, including the type and caloric content of ingested meals, rate of gastric emptying, and small intestinal transit and absorption of nutrients. The small intestine represents the major site of nutrient-gut interactions and associated neurohormonal responses, including secretion of glucagon-like peptide-1, glucose- dependent insulinotropic peptide and somatostatin, which exert pleotropic actions relevant to the postprandial haemodynamic profile. This review summarises knowledge relating to the role of these gut peptides in the cardiovascular response to a meal and their potential application to the management of PPH. Keywords: postprandial hypotension; glucagon-like peptide-1; glucose-dependent insulinotropic Citation: Borg, M.J.; Xie, C.; Rayner, polypeptide; somatostatin; diabetes mellitus; autonomic failure C.K.; Horowitz, M.; Jones, K.L.; Wu, T.
    [Show full text]
  • Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors
    Journal of Nuclear Medicine, published on September 4, 2014 as doi:10.2967/jnumed.114.142000 CONTINUING EDUCATION Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors Clément Morgat1–3, Anil Kumar Mishra2–4, Raunak Varshney4, Michèle Allard1,2,5, Philippe Fernandez1–3, and Elif Hindié1–3 1CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France; 2University of Bordeaux, INCIA, UMR 5287, Talence, France; 3CNRS, INCIA, UMR 5287, Talence, France; 4Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, DRDO, New Delhi, India; and 5EPHE, Bordeaux, France Learning Objectives: On successful completion of this activity, participants should be able to list and discuss (1) the presence of bombesin receptors, neurotensin receptors, or neuropeptide-Y receptors in some major tumors; (2) the perspectives offered by radiolabeled peptides targeting these receptors for imaging and therapy; and (3) the choice between agonists and antagonists for tumor targeting and the relevance of various PET radionuclides for molecular imaging. Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through October 2017.
    [Show full text]
  • Small Cell Lung Cancer Cells: Stimulation by Multiple Neuropeptides and Inhibition by Broad Spectrum Antagonists
    SMALL CELL LUNG CANCER CELLS: STIMULATION BY MULTIPLE NEUROPEPTIDES AND INHIBITION BY BROAD SPECTRUM ANTAGONISTS. A thesis submitted for the degree of Doctor of Philosophy in the University of London by TARIQJ. SETHI July 1993 Growth Regulation Laboratory Department of Cell Biology Imperial Cancer Research Fund University College London London ProQuest Number: 10017254 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10017254 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Human small cell lung cancer (SCLC) constitutes 25% of lung cancers and follows an aggressive clinical course. SCLC is characterised by the presence of intracytoplasmic neurosecretory granules and by its ability to secrete many hormones and neuropeptides. Only bombesin-like peptides, which include gastrin-releasing peptide (GRP), have been shown to act as autocrine growth factors for certain SCLC cell lines. This thesis focused on other neuropeptides and particularly their ability to mediate SCLC growth. The neuropeptides bradykinin, cholecystokinin (CCK), GRP, neurotensin and vasopressin at nanomolar concentrations stimulated an increase in the intracellular concentration of calcium ([Ca^+Jj), inositol phosphate hydrolysis, and increased colony formation in semi-solid medium in responsive SCLC cell lines.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: a Pilot Dose-Ranging Study
    nutrients Article Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study Anne Christin Meyer-Gerspach 1,2,* , Jürgen Drewe 3, Wout Verbeure 4 , Carel W. le Roux 5, Ludmilla Dellatorre-Teixeira 5, Jens F. Rehfeld 6, Jens J. Holst 7 , Bolette Hartmann 7, Jan Tack 4, Ralph Peterli 8, Christoph Beglinger 1,2 and Bettina K. Wölnerhanssen 1,2,* 1 St. Clara Research Ltd. at St. Claraspital, 4002 Basel, Switzerland; [email protected] 2 Faculty of Medicine, University of Basel, 4001 Basel, Switzerland 3 Department of Clinical Pharmacology and Toxicology, University Hospital of Basel, 4001 Basel, Switzerland; [email protected] 4 Translational Research Center for Gastrointestinal Disorders, Catholic University of Leuven, 3000 Leuven, Belgium; [email protected] (W.V.); [email protected] (J.T.) 5 Diabetes Complications Research Centre, Conway Institute University College Dublin, 3444 Dublin, Ireland; [email protected] (C.W.l.R.); [email protected] (L.D.-T.) 6 Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark; [email protected] 7 Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; [email protected] (J.J.H.); [email protected] (B.H.) 8 Department of Surgery, Clarunis, St. Claraspital, 4002 Basel, Switzerland; [email protected] * Correspondence: [email protected] (A.C.M.-G.); [email protected] (B.K.W.); Tel.: +41-61-685-85-85 (A.C.M.-G.
    [Show full text]